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ABSTRACT
Parkinson’s disease is a progressive neurodegenerative disease that causes debilitating
motor deficits in addition to many non-motor symptoms. Tremors, stiffness, and abnormal
gait changes are easily recognized as disabling; however, effects from anxiety are more
insidious to disease burden which negatively affect both motor and psychological
capabilities. Anxiolytics or antidepressants are often prescribed but can cause adverse side
effects, prompting the need for alternative treatments. Yoga and mindfulness therapies are
favorable alternative treatments known to reduce anxiety. This two-arm, single-blinded
randomized controlled trial compares effects of yoga and mindfulness therapies in the
reduction of anxiety for patients with Parkinson’s disease. Yoga is hypothesized to have
greater statistically significant effect in reducing anxiety compared to mindfulness due to
its combined mental and physical benefits. However, if both interventions demonstrate
positive outcomes, both may prove to be beneficial adjunctive treatments for patients with
anxiety in Parkinson’s disease or other neurodegenerative movement disorders.
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CHAPTER 1: INTRODUCTION
1.1 BACKGROUND
1.1.1 Overview of Parkinson’s Disease and Related Anxiety
Parkinson’s disease (PD) is a progressive neurodegenerative disease that results in
debilitating motor and cognitive deficits that drastically decrease quality of life and health
status. There is a direct association between the incidence of PD with aging; as such,
prolonged life expectancies in recent decades contribute significantly to the increase in
diagnoses and subsequent healthcare expenditures.1 In 2020, one million US citizens
were estimated to be living with PD; and the prevalence has been projected to increase by
at least 60,000 patients per year.1 The annual healthcare expenditures were estimated to
be $12,350 - $17,136 per patient in 2020.2
Although the inciting factor triggering idiopathic Parkinson’s disease has not been
identified, the underlying neuropathology and symptomology of Parkinson’s disease have
been well-established. Abnormal α-synuclein accumulations in various cells including
Lewy bodies result in the degeneration of dopaminergic neurons in the substantia nigra.3
The resultant loss of dopamine supply for this area of the brain disrupts the coordination
of movements which results in tremors, bradykinesia, and rigidity. 4,5 Although the
development of motor symptoms is often gradual, actual rates of progression may differ
among each patient. Unfortunately, PD is neither reversible nor curable.
In addition to the more classic motor symptoms of PD, there are psychological
symptoms that accompany the disease. The underlying pathophysiology of the
psychological changes is also not fully understood, but most research in this area has
implicated alterations in dopaminergic system and transporter availability, structural
amygdala changes, and loss of noradrenaline neurons in the locus coeruleus as potential
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etiologies.6 Other neurobiological explanations include disruptions of frontal-striatal
circuits that regulate stress, cognition, affect, motivation, and behavior.7
The diminished abilities to regulate new physical and emotional stressors from
PD often result in secondary diagnoses of anxiety disorders at a later age. Anxiety
disorders as determined by DSM-V have been diagnosed in patients with Parkinson’s
disease and include generalized anxiety disorder (14%), social anxiety disorder (13.8%),
anxiety not otherwise specified (NOS) (13.3%), specific phobia (13%), and panic
disorder (6.8%).5
1.1.2 Treatments of Parkinson-Related Anxiety
A study conducted by Broen et al. in 2016 revealed that 31.1% of patients with
Parkinson’s disease (PwP) had anxiety disorders or clinically relevant anxiety
symptoms.8 Despite being a fairly prevalent symptom experienced by PwP, there are no
formal guidelines for treatment of anxiety in this population.8,9 Several agents including
Bromazepam, selective serotonin reuptake inhibitors (SSRI), and cognitive behavioral
therapies (with or without pharmacotherapy) have been trialed to varying efficacies.10
Many of these therapies also have the potential to lead to adverse drug interactions and
debilitating side effects, sometimes resulting in higher healthcare expenditures.11
In the search for cost-effective therapies, researchers have turned towards
investigating psychological treatments that aim to reduce negativity in internal responses
to emotional or physical situations that may trigger anxiety.12
A precedent has been set for the use of alternative therapies such as mindfulness
or yoga in progressive neurological disorders such as multiple sclerosis (MS) and
Huntington’s disease (HD). These disorders closely resemble PD in their multisystemic
disease course, neurodegeneration, and incurability.7 In a systematic literature review,
3

mindfulness based therapies were found to have a greater positive effect in patients with
MS-related anxiety than antidepressants in patients with PD-related anxiety.7 Although
mindfulness was not studied for PD-related anxiety, the authors suggested that
mindfulness had high potential in reducing PD-related psychological distress.
Mindfulness has been shown to effectively increase self-awareness while
preventing habitual and negative responses to emotions or physical impairments.13 This is
accomplished through increased attention and self-awareness of emotions, sensory
perceptions, and thinking patterns in a non-judgmental manner.10 The response to difficult
situations then becomes slowed and methodical—leading to less anxiety and an enhanced
repertoire of coping skills over time.14 The medial cortex, amygdala, lateral frontal
regions, hippocampus, and basal ganglia have all been studied to be affected by
mindfulness.15 Specifically, it has been demonstrated that mindfulness down-modulates
outputs from the amygdala, which has been associated with reductions in anxiety and
fear-related behaviors.16,17 While there is ongoing investigation on the effect of
mindfulness on other cortical structures, impact studies have demonstrated that
mindfulness has shown positive effects on quality of life based on both mental health and
well-being questionnaires.16
With yoga, the psychological benefits have been associated with relaxation of the
physical body. Research findings indicate that yoga decreases emotional stress and
reduces the autonomic sympathetic, fight-or-flight heightened responses.18 Yoga has also
been shown to directly reduce the oxidative stress that results in dopaminergic
neurodegeneration in the substantia nigra. The oxidative stress involving reactive oxygen
and nitrogen species along with diminished antioxidant protection cause improper
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skeletal muscle contraction and muscle fatigue.19,20 The physical practice of yoga
exercises and poses are known to reduce oxidative stress by increasing both endogenous
enzymatic and nonenzymatic antioxidants.20 The result contributes to a slowing of the
loss of dopaminergic neurons, which in turn reduces the disruption to the previously
described frontal-striatal circuits that control mood and behavior.
Other theorized effects of yoga includes a downregulation of the hypothalamicpituitary-adrenal axis as a means of reducing anxiety.21 Studies in this area have shown
that deep breathing, meditation, and active exercises in yoga correlate with reduced levels
of cortisol and catecholamines, and increased levels of serotonin, melatonin, and GABA.
These changes in neurotransmitter activity have all been implicated in promoting positive
mental health benefits.22 The increase in GABA neurotransmitters in yoga is a
mechanism of action that many anxiolytics, like benzodiazepines, attempt to mimic
exogenously.23 Breath control in yoga has been studied and found to benefit anxiety and
panic disorder by activating the parasympathetic nervous system via vagal stimulation
and reducing the activity of the sympathetic nervous system.23
To date, there have been no head-to-head studies comparing the efficacy of yoga
and mindfulness in decreasing anxiety. It is suspected that yoga may demonstrate a more
significant reduction in anxiety over mindfulness due to combined physical and
neurochemical responses like increased endogenous opioids, which improve moods and
decrease pain.23
1.2 STATEMENT OF THE PROBLEM
Studies have shown that high levels of anxiety lead to accelerated motor
dysfunction, poor treatment compliance, and rejection of leisure and social activities.11
These changes all drastically decrease quality of life.24,25 Many pharmacological agents
5

with anxiolytic properties like SSRI, buspirone, and benzodiazepines have been tried in
Parkinson populations. But, many of these agents block dopamine or increase risk for
falls and confusion, making them especially dangerous in patients with primary physical
and/or cognitive impairments.11 The dopaminergic therapies that are used to alleviate
motor symptoms in Parkinson’s are minimally efficacious toward the psychological
symptoms that patients experience. In some instances, dopaminergic treatments may
worsen such symptoms. Treatment of non-motor symptoms typically subjects patients to
polypharmacy, unwanted side effects, and higher medical expenditures. Despite the
relatively high prevalence of anxiety in patients with Parkinson’s disease, there are very
few studies that address anxiety as primary outcomes;11 or, evaluate non-pharmacological
options for treatments of Parkinson’s-related anxiety.24
1.3 GOALS AND OBJECTIVES
Patients with Parkinson’s disease would benefit from low-cost, low-risk
nonpharmacological therapies designed to improve functional abilities across multiple
domains (physical, cognitive, and mood/affect). Research-based outcomes indicated that
both mindfulness therapy and yoga therapy improve psychological symptoms.26 Our
objective is to determine which therapy has greater impact in reducing anxiety in patients
with Parkinson’s Disease. This study will be designed and powered to examine reduction
of anxiety as the primary outcome. The study will also utilize inventories and indexes
tailored specifically for Parkinson’s anxiety.
1.4 HYPOTHESIS
Patients with Parkinson’s disease who practice yoga weekly for 8 weeks will have
statistically significant mean differences in anxiety scores on the Parkinson Anxiety Scale
(PAS) and Beck Anxiety Inventory (BAI) as compared to patients who practice
6

mindfulness-based therapies for the same number of sessions. We expect to see decreases
in anxiety-related symptoms as our primary outcome. The secondary outcomes will be
improvements in health status, motor symptoms, and changes in anxiety medication
usage. We also hypothesize that the benefits of both therapies will be maintained at 3months and 6-months post-intervention.
1.5 DEFINITIONS
Mindfulness Therapy – conscious awareness, openness, and non-judgment of present
moment
Yoga Therapy – Specific application of yoga activities (postures, breathing, meditation)
used to aid recovery or rehabilitation from illness, injury, or disability22
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CHAPTER 2: REVIEW OF THE LITERATURE
2.1 INTRODUCTION
From August 2020 to May 2021, a systematic literature search was carried out on
PubMed, Cochrane, and Scopus with different combinations of the key terms:
“Parkinson* anxiety”, “Parkinson*” “antidepressants”, “Parkinson* AND tricyclic
antidepressants”, “Beck anxiety Parkinson”, “Parkinson Anxiety Scale”, “CBT”, “yoga”,
“yoga therapies”, “mindfulness”, and “mindful meditation”. The following MeSH
phrases were also used on PubMed: “Parkinson* anxiety”, “yoga”, and “mindfulness”.
Results were narrowed with filters for publication dates in the last decade and the
following article types: randomized controlled trial, meta-analysis, and systematic
literature review. On CINAHL, the following were searched: (MH "Parkinson Disease")
AND (MH "Anxiety+") “yoga therapy” “mindfulness” and “anxiety disorders”. Several
articles were also extracted from the reference lists of other articles.
2.2 REVIEW OF EMPIRICAL STUDIES
2.2.1 Overview of Pharmacological Therapies in Parkinson-Related Anxiety
Systematic literature reviews performed by Broen et al. on Parkinson-related
anxiety revealed that an average of 31% of patients with Parkinson’s disease met criteria
for DSM-V anxiety disorders and another 25.7% for clinically significant anxiety
symptoms.1 Despite the importance of anxiety and psychological disability in PD, there
were limited numbers of well-designed controlled studies regarding prescribing practices
in this population.2 A cross-sectional study by Pontone et al. demonstrated that among 38
patients with Parkinson-related anxiety, only 53% were actively receiving
pharmacological treatment.3 Of those receiving treatment, the most commonly used
anxiolytics were selective serotonin reuptake inhibitors (SSRI), with 30.1% and 38.9%
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prescribed in patients with and without depression, respectively.3 This was in contrast to
benzodiazepines, which were the medication of choice for non-PD populations.3 The
avoidance of benzodiazepines in patients with Parkinson’s (PwP) was based on the
known side effects such as increased fall risks, cognitive impairment, and medication
dependency.3
Although the study by Pontone et al. provided useful documentation of the
prescription patterns in Parkinson-related anxiety, it lacked the details of treatment
schedules and efficacies.4 The study also did not account for the use of alternate, nonpharmacological therapies in Parkinson-related anxiety. Additional studies are necessary
to determine the efficacy of pharmacological treatments as well as the reasons for low
prescription rates.
2.2.2 The Effects of Mindfulness on Anxiety
In recent years, the use of mindfulness-based interventions has become more
prevalent due to its low-cost and convenience as a psychological treatment. Research
pursuits have focused on assessing its efficacy in anxiety syndromes both as an
independent treatment option and as an adjunct to other treatment modalities.5,6
Boettcher and Kladnitski et al. each performed randomized controlled trials and
separately found online mindfulness programs to be effective for primary anxiety
disorders (social anxiety disorder, panic disorder, general anxiety disorder, and anxiety
not-otherwise-specified). In the Boettcher et al. study, 91 patients were assigned to either
an online mindfulness treatment group or an online discussion forum control group.7
Participants showed decreases in symptoms of anxiety, depression, and insomnia with
more notable reductions from pre- to post- assessment (Cohen’s d=1.58) in the
mindfulness group as compared to the control group (d=0.49).7 The primary outcomes
10

measured on the Beck Anxiety Inventory (BAI) also showed large group differences
(d=0.99) post-treatment between the two treatment groups.7,8 Clinically, 16 participants
(40%) of the mindfulness group achieved the criteria of improvement and recovery
compared to 4 participants (9%) in the control group. These differences in response rate
were deemed significant (χ2 = 11.04, p = 0.002).7 However, the anxiety scores between
post-intervention to 6-month follow up were not determined to be significant (t = -0.95,
p=0.347).7
Kladnitski et al. took a similar approach and delivered mindfulness sessions
online over a 14-week period for patients with primary DSM-V based diagnoses of
primary anxiety and major depressive disorders.8 Within the mindfulness group, a
reduction of 1.08 (95% CI of 0.55 to 1.60) was found between baseline and posttreatment, and 1.14 (95% CI of 0.60 to 1.69) from baseline to 3-month follow-up.8 This
was in contrast to the treatment-as-usual (TAU) response of 0.34 (95% CI of -0.14 to
0.82) from baseline to post-treatment. The response from baseline to follow-up was not
reported in the TAU group.8 The comparison of reduction in anxiety between the
mindfulness and TAU interventions was significant at 1.00 (95% CI of 0.46 to 1.54) postintervention. These results were unexpectedly greater than the moderate differences
found in other studies.8 Clinically, 73.1% of the 40 participants in the mindfulness group
no longer met the DSM-V criteria for anxiety or depressive disorders at 3-months followup; however, an attrition rate (23-35%) suggested that these improvements may not be
sustainable.8
The Kladnitski et al. study was sufficiently powered to detect statistically
significant differences between interventions and treatment as usual care, but revealed
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that the benefits of mindfulness may not necessarily be maintained beyond treatment
completion without continued observance of mindfulness practices.8 The authors
surmised that future trials would likely require at least 200 participants in each group to
achieve statistical significance between mindfulness and TAU.8 Based on these findings,
it was also suggested that mindfulness training was a viable stand-alone therapy option
for individuals with anxiety, and that daily use of mindfulness therapy will support longterm benefits.8 Since both Boettcher and Kladnitski et al. concluded that three months
was an insufficient duration to conduct post-treatment follow-up, future studies should
have longer monitoring periods in order to more accurately comment on the long term
efficacy of mindfulness treatments.7,8
Sundquist et al. conducted a head to head comparison study on mindfulness-based
interventions (MBI) against cognitive behavioral therapy (CBT) and pharmacological
treatments.6 Their qualifying inclusion criteria covered a broad range of anxiety disorders
that included all the diagnoses similarly observed in patients with Parkinson’s (panic
disorder, GAD, mixed anxiety and depressive disorder, other mixed anxiety disorders,
and anxiety NOS).6 This study did not target patients with Parkinson’s disease. The MBIs
group had drastically decreased the median scores on the anxiety subscale of the Hospital
Anxiety and Depression Scales (HADS) from baseline to post-intervention assessment (p
< 0.001).6 Primary outcomes of HADS also revealed that MBIs were not inferior to CBT
or pharmacological treatment controls (97.5% one-sided CI with an upper limit 3.16).6
Unfortunately, the study population was restricted to participants 20-64 years old,6 and as
such, results could not be generalized to older populations or Parkinson’s patients, who
are generally >60 years old.9
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Dissanayaka utilized a specific mindfulness training, called Mindfulness-Based
Stress Reduction (MBSR), which facilitates adaptation to the stress and management of
medical illnesses.10 This study was designed specifically to determine efficacy of the
mindfulness training for reduction of motor and neuropsychiatric deficits in PwP.10
Dissanayaka believed that mindfulness practices would improve selective and sustained
attention, working memory, executive functioning, and motor ability, which would prove
especially beneficial for PwP.10 Anxiety-related symptoms were assessed using the
Geriatric Anxiety Inventory (GAI). Outcomes demonstrated that the postintervention
mean GAI scores were significantly reduced from baseline (Z= - 2.20, p=0.03), and that
21% of the 14 participants experienced clinically significant reductions in their anxietyrelated symptoms.10
Limitations to this study were that the sample size was small. Outcomes indicated
no significant differences between the mean GAI scores from baseline to 6-months
follow-up (Z= -1.29, p= 0.20).10 This finding, along with the findings from Kladnitski et
al. study, suggested that the benefits of mindfulness may be nullified if consistent
practice is not maintained post-intervention.10 As for motor symptoms, the scores from
the Movement Disorder Society-United PD Rating Scale did not show improvements in
follow-up and post-intervention from baseline.10
2.2.3 The Effects of Yoga on Anxiety
Yoga promotes both physical and psychological well-being11 through various
techniques that include physical postures (asanas), breath regulation (pranayama),
meditation/mindfulness, and relaxation.12 Over the past two decades, yoga has been
revitalized in mainstream culture, but internationally it has already been accepted as a
form of complementary medicine for both physical and mental health.13-15
13

Cramer et al. conducted a systematic meta-analysis to assess the efficacy and
safety of yoga in patients with a wide scope of anxiety disorders.13 The research included
adults with mean ages 30-38.5 years old, who met DSM-IV criteria for primary anxiety
disorders or who scored moderate or higher for anxiety according to clinical anxiety
rating scales and questionnaires.13 Primary anxiety outcomes included improvements in
the severity of anxiety or complete remission of anxiety based on objective clinicianrated or subjective self-rated scales.13
The meta-analysis revealed that yoga had positive, short-term effects (12 weeks
from randomization) on anxiety compared to no treatment based on standardized mean
differences (SMD) = -0.43; 95% CI = -0.74 to -0.11; P=0.008.13 When compared to other
relaxation techniques such as meditation, yoga showed an even greater reduction of
anxiety (SMD = -0.86; 95% CI = -1.56 to -0.15; P=0.02). The results of this metaanalysis were not without limitations. Beyond the 12 weeks of study, there were no
changes in the remission of anxiety between intervention and control groups.13 Cramer et
al. also found that a statistical significance was not achieved in subjects with DSM-IV
diagnosed anxiety disorders, but was achieved on questionnaires in individuals with selfreported clinical symptoms.13
De Manincor conducted a single-arm crossover RCT to evaluate the effects of
individualized yoga therapies on depression and anxiety.10 101 subjects were enrolled
based on scores obtained from completion of the Depression Anxiety Stress Scale
(DASS-21). The participants were divided up into either the yoga intervention or the nonintervention control group. The control group had a 6-week delay in interventions during
which they maintained regular activities.15 The intervention group participated in six
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weeks of yoga treatment with certified yoga instructors. A total of four group sessions
were held. In each session, the instructors worked with each participant to create
individualized routines that were adapted to the participant’s specific physical and mental
symptoms.15 Individuals were then encouraged to practice these routines at home in
between sessions. Compliance with the home regimen was recorded. These
individualized routines had a mixture of physical postures and movements, breathing
exercises, relaxation, mindfulness, and meditation techniques.15 At 6 weeks, the control
group was started on the same individualized yoga training and treatment schedule.10
On the anxiety subscale of DASS-21, there were no significant reductions of
anxiety between treatment and control groups (AMD -1.91; 95% CI = -4.58 to 0.76;
P=.16, effect size = -0.35).15 The researchers determined some data points to be outliers
due to their Cook’s distance values > 0.04. When these suspected outliers were trimmed,
the pre- and post-anxiety scores became statistically significant in the treatment group
(AMD -2.58; CI: -4.71 to -0.35; P=0.02; effect size -0.40).15 Significant reductions in
scores were also observed in the overall mean composite anxiety, depression, and stress
scores (AMD -8.77; 95% CI = -16.58 to -0.97; P=.03, effect size = -0.50) between the
intervention and control groups at 6 weeks post-intervention (P<0.01).15
The ability to adapt yoga techniques to fit various physical capabilities within the
home environment and without explicit guidance were some of the benefits observed
from these individualized, at-home treatments.15 Overall, psychological benefits were
positive with the yoga interventions, but were not specific to target the anxiety
symptoms. Despite attempts to minimize selection and performance biases, the study
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design introduced heterogeneity within the individualized yoga interventions, making it
difficult to generalize the outcomes to broader groups.
Boulgarides investigated the potential psychological and physical benefits of yoga
specifically for patients with PD. Prior to the initial assessment, a medical history,
Unified PD Rating Scale (UPDRS), and Hospital Anxiety and Depression Scales (HADS)
were performed. The following physical assessments were also performed: Berg Balance
Scale (BBS), Modified Dynamic Gait Index (mDGI), 30-second chair stand (TSCS), Sitand-Reach tests (SRT), Apley’s Scratch test (AST), Functional Reach Test (FRT), and
timed Single-Leg Balance (SLB) test.16
Outcomes from the Boulgarides et al. study were determined through minimal
detectable changes (MDC), which are the amount of measurable changes in test scores
that allow the study to confidently state that the change was not the result of
measurement errors.16 20% of participants achieved MDC for the HADS anxiety
subscale.16 Post-ANOVA analysis revealed statistically significant mean differences in
the 30-second chair stand (TSCS) and bilateral sit-and-reach tests (SRT) at  = 0.10.16
Outcome measures demonstrated significant improvement post-intervention for TCSC ( p
= 0.03) but a lack of significant changes in the controls (p = 0.39).16 The majority of
participants (60%) met the MDC of > 1.64 for TSCS with the yoga intervention.16 SRT
on the right and left side demonstrated significance at p = 0.02 and 0.03 respectively with
70% of participants achieving an MDC of >3 inches between fingertips and toes on the
right and 40% achieving 3.5 inches on the left.16 The study concluded that a sample of 10
participants was sufficient to observe significant differences in the HADS subscales
between control and intervention periods at an  = 0.01. For TSCS, a sample size of 33
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was needed to satisfy an  = 0.01; and for SRT, a sample size of 153 was needed to
detect significant differences at 80% power and 0.01 level of significance.16
Despite a small sample size and low statistical power, Boulgarides et al. found
adequate measures to assess flexibility, strength, motor control, balance, anxiety, and
depression. The study also showed positive effects of yoga on anxiety and certain
physical parameters. Boulgarides et al. also minimized confounders by utilizing the same
cohort for both the control and intervention groups through a waitlist design.
2.3 REVIEW OF POSSIBLE CONFOUNDING VARIABLES
Despite the standardization of the mindfulness or yoga group therapies, the
relationship between participants and instructors occasionally became potential
confounders. Several studies observed variability among the amount of time instructors
spent on each individual, either to encourage adherence or to monitor risk.8 However, the
increased attention from instructors were often found to influence treatment adherence
and thus primary outcomes.8
Among group members, participants showed benefits from positive group
interactions that resulted in greater accountability, increased feedback, and overall social
support and encouragements.17 The social networking and group interactions could also
confound results, especially when they were compared to controls or other interventions
that did not utilize group formats, such as the waitlist controls.8,15
Aside from group therapies, many studies employed home regimens to be
practiced between group sessions. De Manincor et al. customized home routines for each
participant in addition to group yoga lessons. They found that these personalized routines
confounded effects on anxiety and health status depending on compliance with home
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practice times and regimen variabilities.15 The heterogeneity of these routines made it
difficult to determine the efficacy of treatment on the group and also difficult to
differentiate between the efficacy of one personalized routine over another.15
As for participant-dependent confounders, compliance to research protocol to
attend group lessons and to practice home regimens were confounding factors.15 The
effect of participant adherence as a confounding factor was verified when Kladnitski et
al. assessed participants’ expectancy of treatment efficacy in each participant at the
beginning of the study.8 It was determined that adherence was a better predictor of
outcome than treatment expectancy.8 However, the perceived efficacy of treatment was
also a reportable factor in determining the participants’ adherence to protocol.8
Additionally, subjects who have experience with yoga or mindfulness-based
therapies could also affect the association between interventions and anxiety symptom
outcomes.18 Hofmann’s study tried to account for this confounding variable by setting an
ineligibility standard that anyone who had experiences of five or more yoga/mindfulness
sessions would not be enrolled in the study. 11 Because of this enrollment criteria,
challenges were reported regarding enrollment of subjects who were treatment naïve to
both mindfulness and yoga.
2.4 REVIEW OF RELEVANT METHODOLOGY
2.4.1 Study Setting and Design
A literature review was conducted to assess study designs used for yoga and
mindfulness therapies. There was a clear preference to utilize two-arm randomized
control efficacy trials with intervention groups receiving standardized yoga or
mindfulness therapies and control groups receiving a variety of care interventions. These
interventions ranged from standardized CBT, stress education, and stretch resistant
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training,11,19 while other control groups took the form of delayed intervention.16,20 The
interventional groups received weekly, hour-long yoga or mindfulness sessions for 8-12
weeks in groups of 4-6 participants with 1-2 instructors.11,16,18-20 The addition of home
independent regimens varied among the studies. Since yoga and mindfulness have the
greatest impact with consistent practice, the implementation of standardized home
exercises was ideal for maximizing benefits without confounding the effects of the group
sessions. Kwok et al. standardized the home workouts to 20-minute practices twice
weekly with booklets outlining instructions for each exercise.19 Boulgarides et al.
encouraged home practice but required documentation of time spent on each activity
(breathing, meditation, and posing exercises).16 Cheung et al. thought home exercises
would confound results so they refrained from prescribing any independent treatments.20
Randomization and blinding techniques included randomized computer-generated
groups blinded to research assistants collecting the data and the statisticians performing
the data analyses.20 Block permutation stratified by site was utilized in one study to
ensure equal allocation of participants from each recruitment site to either the control or
treatment group.11,21 Both methods were able to minimize selection and evaluator biases.
Other confounders were minimized by matching variables for group formats, frequency,
duration, venue, and number of participants per group.19
2.4.2 Selection Criteria
Participants included in the studies were over 18 years old with moderate PD (as
determined by Hoehn and Yahr scores of 2-3) and formal DSM-V diagnoses including
GAD, social anxiety disorder, panic disorder, or agoraphobia.8,11 The H&Y criteria
excluded participants with either mild PD who were high functioning or those with
severe PD who had no ability to ambulate unassisted.16
19

Comorbid depressive disorders were allowed in these studies, but other
psychiatric disorders including PTSD, substance use, eating disorders, organic mental
disorders, psychosis, bipolar disorders, developmental disorders, or significant suicidal
ideation were excluded.8,11,22 Pontone et al. justified the inclusion of concurrent
depressive disorders by their findings where they found no differences in the class or
dosing of psychiatric medications for anxiety in patients with or without depressive
comorbidities.4 Therefore, depression was deemed an unlikely confounding factor in the
treatment of anxiety.3 However, the other psychiatric disorders were likely to affect the
psychiatric regimen of anxiety or increase the participants’ risk for hospitalization while
in the study.
2.4.3 Patient Recruitment and Screening
Patient recruitment occurred both locally and regionally through convenience
sampling.19 Most local recruitment came from outpatient neurology and movement
disorder clinics while broader populations were reached through Parkinson’s disease
associations, community-based research registries (region dependent), and support
groups. 10,16,20 Many studies tried to reduce selection biases by widening their search to
regional databases like PD associations, support groups, and national research registries.
But there was no evidence to suggest that the socioeconomical or cultural characteristics
of the local populations were not diverse.10 The results from the local populations were
therefore deemed generalizable to a larger population. Another issue with recruiting over
a wide geographic area was the increased travel time for participants and caregivers to
study sites, which risked attrition and noncompliance to group interventions and followups.
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A series of motor and non-motor screening assessments were performed postrecruitment. Motor assessments included: the Movement Disorder Society - United PD
Rating Scale (MDS-UPDRS) and an assortment of physical assessments: Berg Balance
Scale (BBS), Modified Dynamic Gait Index (mDGI), 30-Second Chair Stand (TSCS),
Sit-and-Reach Test (FRT), and timed Single-Leg Balance (SLB) test.16 Non-motor tests
included several anxiety and mood assessments: Hospital Anxiety and Depression
Scale,16 Geriatric Anxiety Inventory,10 Beck Anxiety and Depression inventory20, and
Hamilton Anxiety Rating Scale11. Having both motor and non-motor assessments as part
of the screening process ensured that participants could physically execute yoga poses
and the clinical assessments.
Hofmann et al. found that despite an overall agreement that anxiety symptoms
were captured on various anxiety scales, there was no consensus among authors on the
best cut-off values to determine if symptoms were clinically significant.11 Therefore,
authors set different threshold levels of anxiety based on their own prior experiences or
those found in other studies.1
2.4.4 Data Collection
Most studies performed evaluator-blinded assessments at baseline (week 0), postintervention (week 8 or 12), and at 6 months follow-up.11,16,20 Fewer studies included
mid-intervention assessments.11
The assessments at baseline included informed consent, motor, and non-motor
assessments.16 The same motor and non-motor tests were repeated post-intervention and
at subsequent follow-ups. Assessing outcomes immediately following the intervention
period provided data on the short-term efficacy of yoga and mindfulness. The 6 months
follow-up provided data on the long-term efficacy of these interventions.
21

Most studies intended for participants to maintain consistent practice postintervention until the follow-up assessments. However, since there were no organized
sessions post-intervention, it was difficult to encourage and remind patients to practice at
home. Dissanayaka et al. incorporated a “telephone mindfulness booster session” to
refresh knowledge and skills learned from the interventions but also to encourage
continued practice.10 Based on the above, instead of a telephone session, participants may
benefit from a 3-months follow-up to ensure continued practice of home regimens.
Additional data obtained may find correlations between compliance with anxiety and
motor symptoms.
2.4.5 Outcome Measures
For primary outcomes, there were several studies that used either the Beck
Anxiety Inventory (BAI), Hospital Anxiety and Depression Score (HADS), and Hamilton
Anxiety Rating Scales (HARS). Leentjens et al. sought to validate the clinimetric
properties of HARS, BAI, and HADS.22 The study found that all scales (BAI, HADS, and
HARS) had low positive predictive value and moderate negative predictive value at the
optimal cut-off scores. This resulted in an underestimation of the severity and prevalence
of anxiety in PwP.22
Leentjens et al. then developed a novel scale with improved validity and
clinimetric properties called the Parkinson Anxiety Scale (PAS).23 The scale was
intended to be an assessment of anxiety severity rather than a screening or diagnostic
tool. 23 To create PAS, canonical correlation analysis of questions from HARS, BAI, and
a Rasch analysis were performed and incorporated to fully capture the spectrum of
anxiety symptoms. The outcome resulted in a patient- and observer-rated scale comprised
of 12 items: five items assessing persistent anxiety, four items for episodic anxiety, and
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three items for avoidance behavior.23 Each item scored on a 5-point Likert scale (0=not or
never and 4=severe or almost always).23
Both patient- and observer-rated scales had high AUC (85.1% and 85.9
respectively), sensitivity, and specificity for any anxiety disorder at the optimal cut-off
scores, which was set as the threshold for whether a patient had an anxiety disorder or
not.23 The patient-rated version had better sensitivity (0.81 vs 0.71) but worse specificity
(0.74 vs 0.91) than observer-rated versions.23
Face validity was found higher in PAS than existing scales because PAS was able
to separate clinically evident and relevant domains into separate subscales. PAS was also
more effective in capturing symptoms of anxiety not otherwise specified (NOS)
compared to other anxiety scales, since the symptoms of NOS were specific to
Parkinson’s disease.1,23 The scale eliminated biases towards persistent symptoms that
were observed in HARS or episodic symptoms, as seen with BAI. Group validity in PAS
was good, the AUC and Youden index of PAS was higher than in HARS, BAI, or HADS.
The PAS was validated based on a three-month study period. To date, no
longitudinal studies have been published regarding the sensitivity of the PAS for anxiety
symptom changes beyond a year. In addition, anxiety has not been adequately assessed in
other PD studies. The adjunctive use of the BAI will document the subtleties of episodic
anxiety. This is more reliable to capture the more mild or transient cases of anxiety given
an estimated >50% of patients who have some degree of PD related anxiety.11,24 BAI also
has high internal consistency and test-retest probabilities when assessing the severity of
anxiety symptoms within the mental health populations.11
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For secondary outcomes, most studies had a combination of quality of life, health
status, adherence rates, and motor symptoms.8,13 Health status was an important
therapeutic outcome in many studies as it often determined the subject’s ability to
perform physical, emotional, and social activities.4 Many studies found anxiety was
associated with an additional 17% of variance in health status after controlling for
depression.4 And anxiety was directly associated with poor health status even after
factoring out motor disabilities. Many studies utilized either the Parkinson’s Disease
Questionnaire version-39 or version-8 questionnaires. PDQ-8 is a shortened form of
PDQ-39, which is the most frequently used questionnaire that explores patient-reported
measures of health status. Both assess the impact of Parkinson’s disease on functioning
and well-being across eight different dimensions including relationships, social situations
and communication.25 If PDQ-8 is used in place of PDQ-39, there is no concern that
PDQ-8 will be less sensitive or specific as it has summary indices similar to those of
PDQ-39, with good validity, test-retest reliability, and internal consistency (ICC=0.96).26
As for motor measurements, Dissanayaka used the Movement Disorder Society
Unified PD Rating Scale (MDS-UPDRS) to assess motor disability. Both MDS-UPDRS
and the original UPDRS assess motor function by measuring motor performance,
activities of daily living, mobility, quality of life, and psychological status. 16 The primary
difference is the addition of more detailed instructions and descriptions of methods for
data acquisition in MDS-UPDRS, which allows participant to complete the assessment
without provider input or the need for further clarification.27 MDS-UPDRS was also
found to better differentiate between the nuances of symptom severity.27
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The physical assessments in PwP commonly include: the Berg Balance scale,
modified Gait Index, Functional Reach Test, Sit-and-Reach Test Apley’s Scratch Test,
the 30-second chair stand, and the single leg balance test. In review of these assessments,
Boulgarides found that only the single leg balance test (SLB), sit-and-reach test (SRT),
and the 30-second chair stand (TSCS) demonstrated changes in scores post-yoga
interventions, and thus recommended only using these outcome measures for future
studies.16 Although there are few studies using the SLB, SRT, and TSCS that support the
findings of Boulgarides, for the purposes of this study, these three assessments will
suffice in assessing participants’ function, balance, and strength.16
2.4.6 Sample Size and Statistical Analysis
The meta-analysis performed by Cramer et al. demonstrated that yoga’s effect
size on depression when compared to aerobic exercises was moderate at 0.59.28 When
Kwok et al. conducted their study on the effect of yoga on anxiety, their aim was to
replicate the outcomes. 60-90 participants per arm were calculated to be necessary for
80% power at a 5% level of significance, with an attrition rate of 20-25%.15,19
For statistical analyses, Kladnitski et al. compared baseline group characteristics
and discrepancies among clinical settings using between-subject ANOVAs and chisquare analyses.8 Both normally-distributed dependent and independent baseline
variables between the intervention and control groups were analyzed with t-tests.16 For
variables that were not normally distributed, the Wilcoxon rank sum test and Spearman’s
rank correlation coefficients were used.16 For within-group comparisons, paired t-tests
were used and Fisher’s exact test for categorical variables.20
To identify the differences of mean outcome scores between pre-treatment, posttreatment, and at follow-up, Analysis of Variance (ANOVA) was used given continuous
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outcome variables compared in ≥ 3 groups.16 When comparing treatment effects between
groups, a linear regression was applied after adjusting for the baseline scores and
levodopa levels.20 For studies with wait-list control groups, a linear mixed model was
applied, also after adjusting for baseline scores and levodopa levels.11,20 Primary and
secondary analyses utilized mixed-effects regression models (MRMs) with intention-totreat analysis, minimizing any potential attrition.11
2.5 CONCLUSION
Both mindfulness and yoga have been shown to be as effective and not inferior to
current first-line treatments for anxiety disorders29, such as cognitive behavioral therapy
and pharmacological agents.6 Dissanayaka et al. targeted the use of mindfulness and yoga
to Parkinson-related primary anxiety disorders and found similar positive outcomes.30
Although mindfulness and yoga show efficacy and credibility as stand-alone therapies for
anxiety,8 the long-term effects are not well-established in the PD population. Therefore,
both are better suited as adjunctive treatments rather than primary mainstay treatments of
Parkinson-related anxiety.30 The preferred role as adjunctive therapies was further
examined by Saeed et al. in a systematic literature review, which found a small response
outcome favoring yoga as a stand-alone therapy. It did not determine any benefit from
mindfulness as an effective monotherapy for anxiety.5 Interestingly, all of the mentioned
studies reported no safety risks for either yoga or mindfulness as adjunctive therapies
when used in conjunction with SSRI, anxiolytics, and CBT.5
For study designs, yoga and mindfulness demonstrated reductions in symptoms
when practiced 60-minutes per week for 3-24 weeks.5 Most studies conducted their
interventions in small group sessions of 4-6 participants and 1-2 instructors. In addition to
group sessions, the majority of the studies incorporated additional independent at-home
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exercise routines. The greatest yield was observed when yoga or mindfulness practices
were standardized to reduce potential confounding effects of the group therapies.19
Most studies recruited from local neurology offices but often sampled from
regional sources such as PD associations and support groups. It was noted that when
recruiting from a large geographic area, there was a higher attrition rate due to the
inconvenience of increased travel time.
Participants with moderate Parkinson severity without cognitive impairments or
comorbid mental health disorders were recruited and referred to these studies. Though
most mental health disorders like PTSD, eating disorders, or psychosis were excluded,
comorbid depressive disorders were permissible after Pontone et al. found that it would
not change the treatments for anxiety disorders.3
The spectrum of anxiety disorders including persistent or episodic anxiety
phenomenas31 are now more broadly and accurately captured by the Parkinson Anxiety
Scale.23 However, its novelty and lack of longitudinal studies warrant supplementation
with the Beck Anxiety Inventory or the Hospital Anxiety and Depression Scales to better
capture symptomatic changes over time.32 Secondary outcomes included physical
abilities, quality of life assessments, medication regimens, and other mood
symptoms.11,19,20,30 These outcomes have all been studied with positive outcomes in
studies on yoga and mindfulness therapies. It is likely that this study will not only affirm
these positive outcomes, but also decipher if one practice may be preferred over another.
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CHAPTER 3: STUDY METHODOLOGY
3.1 STUDY DESIGN
The proposed study will utilize a two-arm, single-blinded randomized controlled
trial to examine the efficacy of yoga and mindfulness therapies in patients with
Parkinson-related anxiety. Both treatments will be administered in eight weekly sessions
by two certified instructors using groups of 4-6 patients. The Parkinson Anxiety Scale
(PAS) and Beck Anxiety Inventory (BAI) will be assessed at the following time points:
pre-intervention, post-intervention, 3 months, and 6 months follow-up by research
assistants blinded to the intervention assignments.
3.2 STUDY POPULATION
Patients who received DSM-V based anxiety diagnoses after being diagnosed
with Parkinson’s disease will be eligible for the study. We will be recruiting patients with
moderate Parkinson’s disease as determined by a score of 2-3 on the Hoehn & Yahr
Scale. Patients may be taking pharmacological agents for anxiety, but their dosing must
remain stable for at least 6 weeks prior to enrollment and throughout the study (barring
emergency discontinuation). Participants must be fluent in English and have scored >24
on the Folstein Mini-Mental State Exam (MMSE) to minimize any confounding factors
associated with cognitive impairments.
Patients may have comorbid diagnoses of depression but not PTSD, substance
use, eating disorders, or organic mental disorders. To further minimize confounders,
patients may not have extensive experiences with yoga or mindfulness therapies (no more
than 5 lessons taken in their lifetime). More detailed inclusion and exclusion criteria can
be found in Table 1 below.
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Table 1. Study Eligibility
Inclusion criteria
•
•
•
•
•

•
•
•
•

Exclusion Criteria

Ability to give informed consent
Age > 18
Ability to speak, read, and write
English
New anxiety disorders diagnosed after
Parkinson’s Disease onset
Stable on current medication regimen
for minimum of 6 weeks with
intention of continuing during their
active participation
Folstein Mini Mental State Exam
(MMSE) score >24
Scores 2-3 on Hoehn & Yahr scale
Parkinson Anxiety Scale score ≥ 12
Willingness and ability to perform
yoga and mindfulness interventions
and comply with requirements of
study protocol

•
•

•
•
•

•
•
•

•

Inability to understand study protocol
and informed consent process
Serious medical illness or potential
need for hospitalization that will
interfere with participation in study
Significant suicidal ideation or
behaviors within the past year
Cognitive impairments with score
≤23 on MMSE
Comorbidity of dementia, PTSD,
personality disorder, eating disorder,
psychosis, or bipolar disorder
Prior experiences of more than 5
yoga or mindfulness sessions
Any concomitant psychotherapy
Any physical conditions that
preclude participant from performing
yoga exercises
Frequent alcohol, marijuana/CBD, or
recreational drug use

3.3 STUDY RECRUITMENT AND SAMPLING
The proposed study will recruit all its patients from movement disorder, general
neurology, primary care, and internal medicine clinics within the Yale New Haven
Hospital system and the greater New Haven area. Patients with idiopathic PD who meet
eligibility criteria will be invited to participate in the study.
The screening visit will include the Folstein Mini Mental State Exam (MMSE)
Hoehn and Yahr Rating Scale (H&Y), Parkinson Anxiety Scale (PAS), and Beck Anxiety
Inventory (BAI). The H&Y scale will be rated by the principal investigator, Dr.
Richardson, to determine the severity and progression of the patients’ Parkinson’s
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disease. Patient will need to have an H&Y score of 2-3 and PAS score ≥ 12 for
enrollment. This means that the participants will have moderate Parkinson’s disease
severity and at least mild clinical anxiety symptoms. Formal consent will be obtained
from the participants who meet these screening criteria to be enrolled into the study.
3.4 SUBJECT PROTECTION AND CONFIDENTIALITY
The study will be reviewed by the Human Investigation Committee of Yale
University School of Medicine and the Yale New Haven Health System. All study
personnel and staff will be required to complete the Health Insurance Portability and
Accountability Act (HIPAA) training and the Yale Human Subjects Protection training.
Any extraction of patient information in electronic medical records will be carried out on
university or hospital-approved, encrypted, and secured devices. Protected health
information (PHI) that are non-electronic will be secured in a locked cabinet in the locked
office of the principal investigator, Dr. Diana Richardson where only she and the coinvestigator will have access. Any PHI will be disposed of in a secure manner after
completion of study.
Consent will be provided in written and verbal form by the participant.
Explanation of consent forms will be provided by trained co-investigator or clinical
research assistants and participants will be encouraged to voice any questions or concerns
at the time. The participant will also be allowed to withdraw from the study at any time.
The consent form will include a detailed study description that will outline the duration of
participation as well as the potential risks and benefits of the study. English versions will
be available to the participants, please refer to Appendix A for an example of the
informed consent.
3.5 STUDY VARIABLES AND MEASURES
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3.5.1 Treatment Interventions
Two active groups will participate in eight weeks of interventions. Each session
will consist of an hour-long yoga or mindfulness therapy with two certified instructors in
groups of 4-6. Each yoga and mindfulness session will be matched for group format,
venue, time, and attention during these sessions.
The first session will consist of an overview of the intervention and will set group
and home exercise expectations. For the rest of the mindfulness sessions, participants will
practice a modified Mindfulness-Based Cognitive Therapy (MBCT) routine for
Parkinson’s disease. These are listed in Table 2 and will include formal sitting meditation
exercises, diaphragmatic breathing, and body scanning.
Yoga sessions will be structured to start with warm-up activities (gentle general
movements, poses, breathing, and facial/vocal poses and sounds), then transition to
standing, seated, and lying poses listed in Table 3. Each session will conclude with
meditation and deep relaxation.
All participants will be required to practice 20 minutes of their particular
intervention (yoga or mindfulness) twice a week. The home regimen will be detailed in a
booklet and will reflect the lessons from that prior week.
Table 2. Mindfulness Treatment Schedule
Session

Key topics

Week 1

Introduction to mindfulness
The mental states of “autopilot” and “mindfulness”
First-hand experience of mindfulness: the raisin exercise
Mindfulness practice: body scan

Week 2

Relationships between thoughts and emotions
Awareness of pleasant events
Mindfulness practice: sitting meditation
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Week 3

Mindfulness practice: 3-minute breathing space
Mindfulness practice: mindful stretching and walking
Awareness of unpleasant events

Week 4

Automatic thoughts (autopilot) can lead to emotional distress
Practice of meditation techniques learned previously

Week 5

Sitting meditation focusing on a difficult of stressful situation

Week 6

Thoughts are not facts
Using the 3-minute breathing space in stressful situations

Week 7

Relationships between daily activities and depression
Generate list of pleasure/mastery activities
Identifying relapse triggers

Week 8

Course review
Keeping a long-term meditation practice going

Table 3. Yoga Treatment Schedule

Session

Key topics

Week 1

Introduction to yoga
Yoga pose practice: Tadasana (basic standing pose), Hasta Chakrasana
(standing backward bend), and Supta Padangusthasana (knee straight, belt
over one foot, leg drawn toward head)

Week 2

Yoga pose practice: Tadasana Urdhva Baddha Hastasana (Standing
pose, arms outstretched, fingers intertwined. Palms face forward, then
arms are lifted so palms face the ceiling), Paschimotanasana (knees apart,
forward bend putting hands on chair in front)
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Week 3

Yoga pose practice: Modified Vrksasana (Balanced on one foot, heel of
opposite foot placed on ankle of standing foot. Hand on chair if needed),
Apasana (one knee drawn to chest, then other knee, then both)

Week 4

Yoga pose practice: Virabhadrasana 2 (One leg forward, back foot
slightly turned in. Arms out to sides and head turned in same direction as
front leg), Marichiyasana (Spinal rotation)

Week 5

Yoga pose practice: Modified Trikonasana (one leg forward with toes
forward. Back foot slightly turned in. Arms out at shoulder level), Spinal
rolls (knees bent and foot on floor, knees allowed to fall one direction,
head turned in opposite side)

Week 6

Yoga pose practice: Virabhadrasana 3 (One leg forward with knee
slightly bent. Palms together at chest or raised slightly overhead), Jathara
parivartasana (one leg straight, opposite knee drawn out to the side)

Week 7

Yoga pose practice: Ardha Chadrasana (Legs together, arms overhead,
thumbs intertwined. Stretch done on one side then the other), Setu
Bandhasana (Bridge, with arms at sides, hips lifted off floor

Week 8

Course review
Keeping a long-term yoga practice going

3.5.2 Primary Outcome Measures
The primary outcome measures will demonstrate improvements and remissions of
anxiety symptoms according to the Parkinson Anxiety Scales (PAS) and Beck Anxiety
Inventories (BAI). For PAS, both a patient-rated and an observer-rated scale will be
completed to accurately assess the severity of anxiety symptoms. Both scales will be
comprised of 12 items: five items assessing for persistent anxiety, four items for episodic
anxiety, and three items for avoidance behavior.1 Each item will then be scored on a 5point Likert scale (0=not or never and 4=severe or almost always).1

35

To further capture the full spectrum and progression of a patient’s anxiety
symptoms, self-reported BAI will supplement the PAS. BAI is a 21-item self-reported
inventory that assesses episodic symptoms that have bothered participants in the recent
month, for example, inability to relax, dizziness, or racing heart. Decreases in PAS and
BAI scores over time will signify clinical improvements in anxiety symptoms. For the
schedule of assessments, refer to Table 4.
3.5.3 Secondary Outcome Measures
Secondary outcomes will include any changes in health status scores (PDQ-8) and
motor symptoms as measured by MDS-UPDRS and physical tests. Additionally, any
changes in the patient’s medications for anxiety will be assessed by the PI, Dr.
Richardson at baseline, post-treatment, and subsequent follow-ups.
PDQ-8 will be used to determine any reductions in self-reported health status
outcomes, an important therapeutic outcome in the treatment of Parkinson’s disease. Low
PDQ-8 scores demonstrate strong abilities to perform physical, emotional, and social
activities.2
The patient’s motor symptoms will be evaluated by Dr. Richardson on the
Movement Disorder Society – Unified PD Rating Scale (MDS-UPDRS). MDS-UPDRS
is a clinimetric assessment that rates 65 items that include the non-motor experiences of
daily living, motor experiences of daily living, motor examination, and motor
complications. There will be 20 questions completed by the patient and a fourth section
that will be completed by the medical provider to assess motor fluctuation and
dyskinesias. The minimum detectable change (MDC), which is the amount of change in
test scores needed to ascertain a true measurable change, has not been studied in MDSUPDRS but is 13 points in the original UPDRS.
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The physical tests will include the 30-second chair stand, single-leg balance test,
and sit-and-reach tests. The 30-second chair stand demonstrates function, balance, and
leg strength by counting the number of times the patient can alternate between sitting and
standing without the use of their arms in 30 seconds. The minimum detectable change
(MDC) for this study will be 1.64 repetitions.3 The single-leg balance test measures the
duration a patient can stand on one leg, which is a proxy test for fall risks in older adults.3
Lastly, the sit-and-reach test measures the distance from fingertips to toes when the
patient reaches their hands toward an extended leg while seated on the edge of the chair.
The other side is then repeated in the same way. There is no recorded MDC in PwP but
the MDC is 3 inches on the right and 3.5 on the left in patients with type 2 diabetes.3
3.6 METHODOLOGY
The PAS, BAI, PDQ-8, MDS-UPDRS, and physical assessments will be
administered prior to randomization of participants. In an effort to minimize selection
bias, the study will utilize non-clinical personnel or a third-party statistician to randomize
groups using a computerized random number generator. Participants will either be placed
into (1) yoga and treatment-as-usual group or (2) mindfulness and treatment-as-usual
group. To further minimize selection bias, each participant will be de-identified and
assigned an arbitrary study-related number. The treatment assignments will also be
concealed from the clinical research assistant and medical provider who will be
administering the PAS, BAI, PDQ-8, MDS-UPDRS, and physical exam assessments.4
The two treatment groups will be matched closely on group formats, frequency (8
weeks), duration (60 minutes), number of participants per group (4-6), and venue. Each
of the mindfulness and yoga group sessions will undergo monitoring to ensure adherence
to treatment protocols. Each session will be audio-recorded and 20% of each recording
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will be graded to ensure that the participants receive appropriate forms of treatment,
comparable instructions, and similar amount of attention from instructors. The
mindfulness and yoga instructors will collect the home regimen diary, documenting
adherence to the assigned therapy (20 minutes of daily practice, twice a week). These
records will then be given to the research assistants.
The MBCT and yoga therapies have all been adapted to fit the physical
capabilities of PwP, and previous studies have reported no specific safety concerns.
However, adverse events will be monitored directly by the two instructors during the
group sessions as participants will be exposed to new techniques of mindfulness or yoga
during that time.
3.7 DATA COLLECTION
The timing of each assessment is listed in Table 4. Once consent has been
received from each participant, they will undergo assessment and interviews with the
clinical research assistant (CRA) to gather baseline demographics (age, sex, years of
education, family history of Parkinson’s or psychiatric disorders). Therapeutic and
histories will be obtained to determine anxiolytic regimen and for other medical histories
that may affect study.
At baseline, both the evaluator- and self-rated Parkinson Anxiety Scale (PAS) and
Beck Anxiety Inventory (BAI) will be administered, which will continue postintervention, at the 3 months, and 6 months follow-up. For secondary measures, the PI,
Dr. Richardson, will assess for any changes in physical abilities using MDS-UPDRS and
other required physical assessments (30-second chair stand, single-leg balance test, and
sit-and-reach tests). The PDQ-8 will also be administered, and the clinical research
assistant will interview the patient to elucidate pharmacologic adherence and any changes
38

in anxiolytic regimen. Follow-up appointments will be in-person and scheduled at the
post-intervention visit with email and phone reminders sent out the day before to prevent
attrition.
Table 4. Timeline of Assessments
MDSUPDRS
Informed
Medical H&Y
PAS,
PDQDemographics
MMSE
Anxiolytics
and
Consent
Review Scale
BAI
8
Physical
Tests
Screening

X

X

X

X

X

X

Baseline

X

X

X

X

Post-Tx

X

X

X

X

3 mo f/u

X

X

X

X

6 mo f/u

X

X

X

X

Note: f/u = follow-up
3.8 SAMPLE SIZE CALCULATION
For a clinically significant effect size of 0.6 to be detected, a 2.1 and 3.4 points
difference on PAS and BAI respectively would need to be measured between baseline
and post-intervention. The study will utilize Cohen’s categories in determining
magnitude of overall effect with a small differential ranging from SMD = 0.2-0.5;
medium from SMD = 0.5-0.8, and large SMD>0.8.5 This study will aim for a moderate
effect size of SMD ≈ 0.6 given the time and resource constraints of the study while
maintaining a power of 80% and an alpha of 0.05. The sample size will include 69
participants per group, assuming from previous studies that a maximum of 20% of
participants may withdraw.
3.9 ANALYSIS
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The intention-to-treat principle will be applied to all statistical tests to reduce
attrition. Demographic and Parkinson diagnostics features between both groups will be
analyzed using Welch’s t-test or chi-square tests. For within-group comparisons, paired ttests will be used and Fisher’s exact test for categorical variables.
Short-term, medium-term, and long-term outcomes will be analyzed separately
with short-term outcomes defined as post-intervention (week 8), medium-term as 3
months follow-up, and long-term as 6 months follow-up.
Standardized mean differences (SMD) with 95% confidence intervals will be
calculated from mean differences divided by pooled standard deviation for primary and
secondary outcomes.5 Negative SMD will indicate beneficial effects of yoga or
mindfulness at post-intervention or follow-ups compared to baseline. Repeated measures
of Analysis of Variance (ANOVA) will be used when assessing for change in more than
two time points, such as when assessing for the changes in anxiety scores, PDQ-8, and
MDS-UPDRS. For all procedures, the statistical tests will be 2-tailed with an alpha set at
0.05.
Table 5. Demographics and Analysis
Yoga and TAU
(N = 69)

Mindfulness and
TAU (N = 69)

Test for Significance

Demographic Features
Age (y), mean (SD)

Paired t-test

Sex (male/female)

2

Years of education, mean
(SD)

Paired t-test

MMSE, mean (SD)

Paired t-test

Health Status (PDQ-8),
mean (SD)
Family history of PD, %
(N)

Paired t-test
2
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Family psychiatric
history, % (N)

2

PD Features
Age symptom onset (y),
mean (SD)
Symptom duration mean,
(SD)

Paired t-test
Paired t-test

Hoehn & Yahr stage

2

Presence of unpredictable
off periods, % (N)
Total levodopa
equivalents, mean (SD)
Psychiatric Features and
Comorbidities
Presence of comorbid
depressive disorder, %
(N)
Presence of multiple
anxiety disorders, % (N)
Current Anxiolytic
regimen (% Daily/PRN)
Compliance of Study
Interventions
Mean sessions attended
(Total = #)
Mean home practice
minutes/week (range)

2
Paired t-test

2
2
2

Paired t-test
Paired t-test

3.10 TIMELINE AND RESOURCES
Once the study application is submitted and IRB approval is obtained, recruitment
in movement disorder, general neurology, and primary care clinics within the Yale New
Haven Hospital System and greater New Haven area will commence. Site recruitment
and participants referrals will be ongoing for 12 months or until the enrollment goal has
been achieved.
During the recruitment period, those who meet eligibility criteria will be invited
to the study. Once screening and enrollment are completed, the participants will be
randomized to an intervention group where they will complete an eight-week course of
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either yoga or mindfulness interventions with 6 months of follow-up. The entire study
will be expected to finish under two years.
A binder will include all consent forms and the number/letter assignments of the
participants. There will be separate participant folders for all the surveys and
questionnaires. All binders and folders will be placed in a locked cabinet in Dr.
Richardson’s office where only the investigators and clinical research assistants will have
access.
Study personnel will include:
▪ Principal investigator and co-investigator: Dr. Diana Richardson and Winifred
Tung, PA-SII
▪ Clinical research assistants (1 per 12 patients)
▪ 2 yoga instructors and 2 mindfulness instructors
▪ Third-party statistician/data analyst
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CHAPTER 4: CONCLUSION
4.1 ADVANTAGES AND DISADVANTAGES
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In the recent decade, validation studies have been conducted on the safety of yoga
and mindfulness for patients with Parkinson’s disease (PwP). However, none of these
studies assessed their effects on anxiety specifically in this population. There are a
limited number of clinical measures available to track the severity of anxiety associated
with Parkinson’s disease. The scales that are available are often too specific and do not
capture the full spectrum of anxiety disorders. This study addresses gaps in both the
measurement and management of Parkinson-related anxiety by 1) using adaptive yoga
and mindfulness regimens to reduce anxiety symptoms in patients with moderate PD, and
2) by using an assessment appropriate for measuring anxiety in Parkinson’s disease.
The Parkinson Anxiety Scale (PAS) has high sensitivities and specificities for a
wide range of DSM-V based anxiety disorders. Although the PAS has been validated in
this study population for the assessment of anxiety disorders, it requires supplementation
with additional rating scales due to the need for a more longitudinal assessment tool.1
Researchers have suggested the use of BAI to supplement PAS when assessing
longitudinal changes of anxiety in this population. Although there is a 6-month follow-up
in this study, it is insufficient to determine any long-term benefits of yoga or mindfulness.
Future studies may benefit from including a longer monitoring period.
There may have been confounding effects of sample bias if participants enrolled
into the study with preconceived expectations of the benefits of yoga or mindfulness
therapies. In this case, they may have been more motivated to practice at home or
minimize their anxiety when completing questionnaires.2 One way to combat the placebo
effect in future studies is to screen participants for preconceptions or assumptions they
may have for the efficacy of yoga. Another potential confounder is that the group
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sessions share features of a support group atmosphere, fostering placebo effects. This
effect may not occur at the follow-up visits, where the participants are solely completing
home individualized exercises. These potential confounders will all need to be further
explored in future studies with longer periods of follow-up.
As yoga and mindfulness practices become more mainstream in the community,
there is greater feasibility of using these interventions as therapies. There likely will be
few barriers to hiring certified instructors to lead modified mindfulness and yoga
treatment sessions. Additional studies would be appropriate to determine efficacy across
the spectrum of the PD population. The mindfulness and yoga programs used in the study
were scripted, so we cannot assume that other programs in the community would be
tailored to the PD population. Instead, comparisons of various modified yoga or
mindfulness programs will be useful to determine the most suitable regimen for PDrelated anxiety disorders.
4.2 CLINICAL AND/OR PUBLIC HEALTH SIGNIFICANCE
The advantages of yoga and mindfulness as adjunctive therapies are two-fold:
addressing anxiety at a low-cost and minimizing polypharmacy. Since Parkinson’s
disease (PD) is a chronic neurological condition, rehabilitation is usually limited to
periods of exacerbation or functional decline due to cost.2 Unlike the accepted referrals to
rehabilitation for motor deficits, symptoms of anxiety are often inadequately addressed
by clinicians. Since yoga and mindfulness regimens can be adapted and practiced at home
for management of anxiety, the cost of therapy is minimal in comparison to potential
hospitalizations or medications. The benefits of the yoga or mindfulness regimens will
also have cumulative and lasting positive effects.
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Polypharmacy in patients with Parkinson’s disease (PwP) is common where four
or five classes of dopaminergic medications may be prescribed. This is then often
combined with anxiolytics and other medications for non-neurological conditions. Many
of these medications may have side effects such as nausea, vomiting, and drowsiness.
The advantages of modified yoga and mindfulness are avoidance of pharmacological side
effects in addition to minimal safety risk for falls or injury.
The prevalence rates of anxiety among PwP vary widely (6-55%) and lifetime
prevalence rates far exceeds that of the general population.3 Since anxiety significantly
affects quality of life, sleep, concentration, and energy levels2, patients suffering from
PD-related anxiety need therapies that will directly address the psychological and
physical consequences of their symptoms. Both yoga and mindfulness have been found to
improve health status while decreasing stress and clinical symptoms of anxiety.
Additional studies are warranted to fully explore the benefits of these therapies in
Parkinson’s disease and similar neurodegenerative illnesses.
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Appendix A: Consent and Privacy Rule Authorization Form
CONSENT FOR PARTICIPATION IN A RESEARCH STUDY
Adapted from 200 PR.1 Informed Consent for Research Participation: Competent Adult
Participants

Title of Study: The Effects of Yoga Versus Mindfulness on Anxiety in Individuals with
Parkinson’s Disease
Principal Investigator: Diana Richardson, M.D.
Co-Investigator: Winifred Tung, PA-SII
Affiliation: Yale New Haven Hospital and Yale School of Medicine
Invitation to Participate and Study Purpose:
We would like to extend an invitation to participate in our study of yoga and mindfulness
therapies for Parkinson-related anxiety. You have been referred because you have been
previously diagnosed with Parkinson’s disease as well as with an anxiety disorder. The
current study will enroll 120 total participants from primary care, internal medicine,
general neurology, and neurology movement disorder clinics in the YNHH system and
within the greater New Haven area. Active participation in the study will require a total
of 10 months from enrollment and baseline assessments to the last follow-up.
To decide your willingness to participate, please continue to read the following details
about the study. A research staff member will then review the purpose, procedures, risks,
and benefits of the study and to make sure that all questions or concerns are addressed.
Description of Study and Procedures:
▪

Enrollment in this study requires that you meet set inclusion and exclusion
criteria. These criteria are as follows:
Inclusion criteria

•
•
•
•
•

•

Exclusion Criteria

Ability to give informed consent
Age > 18
Ability to speak, read, and write
English
New anxiety disorders diagnosed after
Parkinson’s Disease onset
Stable on current medication for
minimum of 6 weeks with intention of
continuing stable dose
Folstein Mini Mental State Exam
(MMSE) score >24
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•
•

•
•
•

Inability to understand study protocol
and informed consent process
Serious medical illness or potential
need for hospitalization that will
interfere with participation in study
Significant suicidal ideation or
behaviors within the past year
Cognitive impairments with score
≤23 on MMSE
Comorbidity of dementia, PTSD,
personality disorder, eating disorder,
psychosis, or bipolar disorder

•

•
•

▪

▪

▪

▪

Willingness and ability to perform
yoga and mindfulness interventions
and comply with requirements of
study protocol
Assessment on Hoehn & Yahr scale is
stage 2-3
Parkinson Anxiety Scale score ≥ 12
for enrollment

•

Prior experiences of more than 5
yoga or mindfulness sessions
Any concomitant psychotherapy
Any physical conditions that
preclude participant from performing
yoga exercises
Frequent alcohol, marijuana/CBD, or
recreational drug use

•
•

•

A written informed consent form (this document) is to be signed by both you, the
participant, and the Primary Investigator (Dr. Diana Richardson) or CoInvestigator (Winifred Tung, PA-SII). The purpose of this informed consent is to
outline the study purpose and study designs so that you will understand your
responsibilities as a participant in the study. Enrollment in this study is optional.
Once enrolled, you may discontinue your enrollments at any time with
notification to the PI.
Following enrollment in the study, additional demographic and pertinent medical
history will be obtained regarding your diagnosis of Parkinson’s disease and of
your diagnosis of anxiety. We will also require a detailed list of your current
medications and may request additional information of relevant family medical
history. If needed, we may request that you provide medical records from doctors
who manage your Parkinson’s Disease and your anxiety. This study is HIPAA
compliant so that no personal identification information will be associated with
the study documents completed as a result of your participation.
During your participation in this study, you will complete various written and
physical evaluations. These assessments will be performed on five different visits
throughout the 10-month period. The written assessments will be questionnaires
regarding your anxiety symptoms, thinking ability, and physical abilities. There
will also be three physical tests to determine strength, ability to maintain balance,
and fall risks.
Below is a chart indicating the activities that will occur at each rating visit:
MDSUPDRS
Informed
Medical H&Y
PAS,
PDQDemographics
MMSE
Anxiolytics
and
Consent
Review Scale
BAI
8
Physical
Tests

Screening

X

X

X

X

X

X

Baseline

X

X

X

X

Post-Tx

X

X

X

X
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3 mo f/u

X

X

X

X

6 mo f/u

X

X

X

X

▪

▪
▪

You will be assigned to one of two treatment groups by a random process such
that each group will have an equal number of participants with similar degrees of
Parkinson’s and anxiety. One treatment group will receive yoga therapy and the
other group will receive the mindfulness therapy. Each group will meet once a
week for 60 minutes for 8 consecutive weeks. Each group will have 3-5 other
participants, including yourself, and 1-2 instructors. Details of these therapies will
be explained in full prior to and at the treatment sessions. You will be required to
attend each treatment session, and the need to make-up sessions will be evaluated
on a case-by-case basis.
In the case that you miss more than 2 treatment sessions or rating sessions, you
will be automatically un-enrolled from the study.
In addition to group sessions, there will be detailed yoga or mindfulness home
exercises to complete. You will be required to complete these twice per week and
record the times in a diary. The exercises will reflect what is learned in the
preceding group sessions that week.

Risks or Inconveniences:
This study is deemed low to no risk. There are no specific physical risks associated with
participation in this study. Due to the nature of Parkinson’s disease, baseline physical
symptoms may increase risks for falls. The yoga and mindfulness interventions have been
adapted for Parkinson’s disease and tested in previous studies with no adverse
consequences. As for anxiety symptoms, yoga and mindfulness are not expected to
worsen any symptoms.
Expected Benefits:
The mindfulness or yoga therapies may improve anxiety symptoms and reduce the need
for anxiety medications. They may also benefit physical abilities, mood, and thinking
abilities.
Economic Considerations:
There will be no costs for participation in the study; however, there will also be no paid
reward for enrollment in the study.
Confidentiality of Information:
Any identified information obtained or reviewed in this study will remain confidential
and only disclosed as require by the United States or Connecticut law. Only the parties
listed in the research authorization form attached will be granted access to identifiable
information we collect. When the study is published, there will be no information that
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will link your identity to the study unless you give specific permission to disclose
personal information.
If needed, your information in electronic medical records will only be accessed through
university approved, encrypted, and secure electronic devices. All healthcare providers
will be subject to the Health Insurance Portability and Accountability act (HIPAA). Any
data on paper will be kept in binders in a locked cabinet in the locked office of the
principal investigator.
Research Subject’s Rights
You are able to decline enrollment into the study and may discontinue participation at
any point throughout the study. However, any data gathered prior to withdrawing
participation may still be used in the study analyses to ensure study integrity and study
oversight. There will be no penalty or loss of benefits associated with withdrawal of
participation. Please notify the Primary Investigator, Dr. Diana Richardson or CoInvestigator, Winifred Tung, PA-II, with a written notice if you choose to withdraw.
Authorization:
I have read (or have ben read) this form and have decided to participate in the project
described. The general purpose, risks, and benefits are clear and acceptable to me.
By signing this form, I give permission to researchers to use information about myself
and my child for the purposes described in this form. By declining participation, I
understand that I will not receive the therapies in this study.
Name of Participant (Print): ___________________
Signature of Participant: __________________

Date: ______________

Name of Person Obtaining Consent (Print): ______________________
Signature of Person Obtaining Consent: ________________Date: ______________
Any further questions or concerns about this research project may be directed to the
Principal Investigator at her office: Dr. Diana Richardson 203-932-5711 x 4724
If after you have signed this form you have any questions about your privacy rights,
please contact the Yale Privacy Officer at 203-432-5919.
If you have questions about your rights as a research participant, or you have complaints
about this research, you can contact the Yale Institutional Review Boards at 203-7854688 or email hrpp@yale.edu.
YALE UNIVERSITY
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RESEARCH AUTHORIZATION

Subject Name:
Medical
Record #:
Principal
Investigator:

IRB #:

Principal
Investigator’s
Contact
Information:

To the Subject:
The health-related information that we gather about you in this study is personal. The Yale School
of Medicine and the Yale New Haven Hospital researchers are required by law to protect the
privacy of the information known as protected health information or PHI. All reasonable efforts
will be made to protect the confidentiality of your PHI, which may be shared with others to support
this research, to conduct public health reporting, and to comply with the law as required. Despite
these protections, there is a possibility that information about you could be used or disclosed in a
way that it will no longer be protected by federal law. For example, some of the individuals listed
on page 2 of this form may not be required by law to meet HIPAA standards for privacy of health
information. These individuals or companies are nonetheless required through other agreements
with Yale to keep your information confidential.
In this form, we describe who will be working with this information and ask for your permission
to use the information in the research study.
Please read this form carefully. If you have any questions, please ask the Principal Investigator
listed above before signing this form.
By signing this form, you give permission for the researchers to use and/or disclosure the
information as described below, for this research study. The reason for the uses and disclosures is
to assess yoga and mindfulness effects on anxiety symptoms related to Parkinson’s disease.
You have a right to refuse to sign this form. Your health care outside the study, the payment for
your health care, and your health care benefits will not be affected if you do not sign this form.
If you do not sign this form, you will not be able to enter this research study and will not receive
treatment as a study participant.
If you sign this form, you may change your mind at any time, but the researchers may still use the
information collected before you changed your mind in order to complete the research.
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This form will never expire unless and until you change your mind and retract it. To retract the
permission to use your information, please tell the study staff or write to Dr. Diana Richardson or
Winifred Tung, PA-SII.
You will not be allowed to see or copy the part of your medical records that describe a research
treatment until the research is completed, but you may see and copy the research treatment
information at the end of the research in agreement with institutional medical record policies.
You have a right to receive a copy of this form after you have signed it. If after you have signed
this form you have any questions about your rights, please contact the Yale Privacy Officer at
203/436-3650.

Use and Disclosure Covered by this Authorization
(1)

Who will disclose, receive, and/or use the information?
The following person(s), class(es) of persons, and/or organization(s) may share, use, and receive
the
information listed below in connection with this Study. These persons are authorized to use and
disclose the information to the other parties on this list, to you or your personal representative, or
as permitted by law.

❑

The following health care facilities or research site(s) and research staff involved in this study:
YNHH, Yale School of Medicine, Research Investigators, Clinical Research Assistants

❑

Health care providers at your PCP, neurology, or movement disorder clinic who referred and
connected you to this study

❑

Laboratories and other individuals and organizations that analyze your health information in
connection with this study, in accordance with the study’s protocol

❑

The members and staff of the Human Investigation Committee that approved this study

❑

Those individuals at Yale who are responsible for the financial oversight of research
including billings and payments

❑

Principal Investigator: Dr. Diana Richardson

❑

Additional members of the Research Team

❑

Data and Safety Monitoring Boards and others authorized to monitor the conduct of the Study

❑

Others (as described below)

(2)

What personal health information will be used or disclosed?
The following information about you may be used and disclosed:

❑

Research study records.

❑

Medical and laboratory records of only those services provided in connection with this Study.
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❑

The entire research record and any medical records held by Yale New Haven Hospital created
from: _Parkinson’s disease diagnosis________ to: ___present_____

❑

The following information:

Signature
I have read this form and all of my questions about this form have been answered. By signing below, I
authorize the described uses and disclosures of information.
_________________________________________
Signature of Subject or Personal Representative
_________________________________________
Print Name of Subject or Personal Representative
_________________________________________
Date
_________________________________________
Description of Personal Representative’s Authority

THE SUBJECT OR HIS OR HER PERSONAL REPRESENTATIVE MUST BE PROVIDED
WITH A COPY OF THIS FORM AFTER IT HAS BEEN SIGNED

Reviewed and Acknowledged
________________________________

Human Investigation Committee
Yale University

Appendix B: Hoehn & Yahr Rating Scale*
• Stage 0 indicates no sign of disease
• Stage 1 indicates unilateral disease
• Stage 2 indicates bilateral disease without impairment of balance
• Stage 3 indicates mild to moderate bilateral disease with some postural instability,
but physically independent
• Stage 4 indicates severe disability, but able to walk or stand unassisted
• Stage 5 indicates confinement to bed or wheelchair unless aided by someone else
* Interpretation of rating scale results: Hoehn & Yahr Stage 0 & 1 (mild), Hoehn & Yahr
Stage 2 & 3 (moderate), Hoehn & Yahr Stage 4 & 5 (advanced)

52

Appendix C: Folstein Mini-Mental State Examination (MMSE).

*Used to assess cognitive and mental faculties; scores 24-30 indicates normal cognition.

Appendix D: Parkinson Anxiety Scale
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Appendix E: Beck Anxiety Inventory
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Appendix F: Parkinson’s Disease Questionnaire (PDQ-8)
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PDQ-8 will assess health status across eight different dimensions including relationships,
social situations and communication.
Appendix G: Movement Disorder Society – United Parkinson’s Disease Rating Scale
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Appendix H: Adaptive Yoga Poses and Descriptions.
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Appendix I: Adaptive Mindfulness Descriptions
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Adapted from Kabat-Zinn’s Mindfulness Based Stress Reduction

Appendix J: Participant Diary of Home Regimen

Subject #
Date

Amount of Time

Week 1
Week 1
Week 2
Week 2
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Appendix K: Sample Size Calculation

Sample size calculations were performed with Glimmpse. Power calculations indicated a
sample size of at least 55 participants were needed to detect a 1 SD difference between
groups in the primary outcome anxiety measures. This means 2.1 and 3.4 points
differences on PAS and BAI respectively. An attrition rate of 20% was accounted for,
which brings the total of participants per group to 55/0.8 = 68.75 persons, rounded to 69
persons.
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